<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?OLF?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><?covid-19-tdm?><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Clin Pharm</journal-id><journal-id journal-id-type="iso-abbrev">Int J Clin Pharm</journal-id><journal-title-group><journal-title>International Journal of Clinical Pharmacy</journal-title></journal-title-group><issn pub-type="ppub">2210-7703</issn><issn pub-type="epub">2210-7711</issn><publisher><publisher-name>Springer International Publishing</publisher-name><publisher-loc>Cham</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7203261</article-id><article-id pub-id-type="publisher-id">1049</article-id><article-id pub-id-type="doi">10.1007/s11096-020-01049-6</article-id><article-categories><subj-group subj-group-type="heading"><subject>Commentary</subject></subj-group></article-categories><title-group><article-title>Covid-19 and drug therapy, what we learned</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-7132-000X</contrib-id><name><surname>Provenzani</surname><given-names>Alessio</given-names></name><address><email>aprovenzani@ismett.edu</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Polidori</surname><given-names>Piera</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><institution-wrap><institution-id institution-id-type="GRID">grid.419663.f</institution-id><institution-id institution-id-type="ISNI">0000 0001 2110 1693</institution-id><institution>Department of Clinical Pharmacy, </institution><institution>Mediterranean Institute for Transplantation and Advanced Specialized Therapies (ISMETT), </institution></institution-wrap>Via E. Tricomi n. 5, 90127 Palermo, Italy </aff></contrib-group><pub-date pub-type="epub"><day>7</day><month>5</month><year>2020</year></pub-date><fpage>1</fpage><lpage>4</lpage><history><date date-type="received"><day>17</day><month>3</month><year>2020</year></date><date date-type="accepted"><day>27</day><month>4</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; Springer Nature Switzerland AG 2020</copyright-statement><license><license-p>This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">COVID-19, the disease associated in December 2019 with the novel coronavirus SARS-CoV-2, was observed for the first time in China and then spread worldwide becoming pandemic. Currently, there is still no licensed specific antiviral treatment for the human coronavirus disease and a vaccine will not be ready soon. However, based on experience from the use of other antiviral agents to treat similar virusses, some treatment options have been tried with some efficacy. Clinical trials for future therapies are still ongoing. In the meantime, prevention, control, active communication and investment in research are the only ways to overcome this challenge.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Antiviral treatment</kwd><kwd>Coronavirus</kwd><kwd>COVID-19</kwd><kwd>SARS-CoV-2</kwd></kwd-group></article-meta></front><body><p id="Par2">Since 31 December 2019, COVID-19, the disease associated with the novel coranovirus Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), caused so far thousands of confirmed cases and deaths all over the world [<xref ref-type="bibr" rid="CR1">1</xref>].</p><p id="Par3">This virus was observed for the first time in Wuhan, China, and very quickly has spread outside Chinese border affecting most of the world becoming no longer an outbreak, but officially a pandemic [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>].</p><p id="Par4">COVID-19, like the Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS), belongs to the group of ribonucleic acid (RNA) viruses that circulate among animals with some of them also known to infects humans [<xref ref-type="bibr" rid="CR4">4</xref>]. These viruses are very common in the world and are so called because of the crown-shaped tips that are present on their surface [<xref ref-type="bibr" rid="CR5">5</xref>].</p><p id="Par5">Coronaviruses are the largest group of viruses belonging to the <italic>Nidovirales</italic> order, which includes <italic>Coronaviridae</italic>, <italic>Arteriviridae</italic>, and <italic>Roniviridae</italic> families. The <italic>Coronaviridae</italic> are further divided into four groups: alpha, beta, gamma and delta coronaviruses [<xref ref-type="bibr" rid="CR6">6</xref>&#x02013;<xref ref-type="bibr" rid="CR9">9</xref>]. SARS-CoV-2, belongs to the beta coronavirus cluster [<xref ref-type="bibr" rid="CR6">6</xref>].</p><p id="Par6">Currently, there is still no licensed specific antiviral treatment for the human coronavirus disease and a vaccine will not be ready soon. Treatment is therefore based on the patient's symptoms and supportive care [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR10">10</xref>].</p><p id="Par7">So far, although scientific evidence is limited, existing drugs approved for other indications have been used to treat COVID-19 [<xref ref-type="bibr" rid="CR10">10</xref>].</p><p id="Par8">Based on the proven efficacy against SARS-COV, the second-generation protease inhibitor lopinavir, approved for the treatment of HIV in combination with a low dose of ritonavir to increase its plasma half-life, has been used to treat COVID-19 [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. However, despite the use of lopinavir/ritonavir in combination with ribavirin was initially considered a promising therapy for treating COVID-19 infections [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>], a recent study comparing a group of patients treated with lopinavir/ritonavir and standard treatment (n&#x02009;=&#x02009;99) versus a second group treated with standard treatment alone (n&#x02009;=&#x02009;100) [<xref ref-type="bibr" rid="CR12">12</xref>] showed that the use of lopinavir&#x02013;ritonavir association had no benefit compared to standard treatment alone [<xref ref-type="bibr" rid="CR12">12</xref>]. The standard treatment was based on the administration of oxygen, invasive and non-invasive ventilation, antibiotics, vasopressor drugs, possible dialysis and extracorporeal oxygenation (ECMO) [<xref ref-type="bibr" rid="CR12">12</xref>].</p><p id="Par9">However, as reported also by the authors, this study had several limitations, one of all the lack of blindness and inhomogeneity of the arms with respect to some patients characteristics such as the severity of the disease and the onset of baseline symptoms [<xref ref-type="bibr" rid="CR12">12</xref>].</p><p id="Par10">The results of this study are therefore not transferable to stable patients and with less serious clinical symptoms.</p><p id="Par11">Other authors suggest that interferon-&#x003b1;, a broad spectrum antiviral drug used for the treatment of hepatitis, administered by inhalation is also helpful in inhibiting the virus [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR13">13</xref>].</p><p id="Par12">Also, the last version (7th edition) of the Guidelines for the Prevention, Diagnosis, and Treatment of Novel Coronavirus-induced Pneumonia [<xref ref-type="bibr" rid="CR14">14</xref>] included as useful therapy, together with the antimalarial chloroquine and the antiviral treatment for influenza arbidol, the broad-spectrum antiviral agent Ribavirin, a guanosine analogue used to treat several virus infections like hepatitis C virus, respiratory syncytial virus and viral hemorrhagic fevers. However, for its undesiderable side effect like anemia, the use of ribavirin may not be convenient in patients who are already very compromised such as those with COVID-19 [<xref ref-type="bibr" rid="CR13">13</xref>&#x02013;<xref ref-type="bibr" rid="CR15">15</xref>].</p><p id="Par13">A recent single arm study performed on 20 COVID-19 patients shows that the use of hydroxychloroquine also by adding the antibacterial drug azithromycin is efficient in viral load reduction/disappearance [<xref ref-type="bibr" rid="CR16">16</xref>]. Hydroxychloroquine and chloroquine's antiviral activity appears to be due to the increase in endosomal ph which is crucial for virus-cell fusion [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. Azithromycin, in addition to inhibiting the protein synthesis of bacteria, is able to mitigate inflammation and modulate the immune system [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>].</p><p id="Par14">However, this study has important methodological problems: non-randomized study, small sample size (n&#x02009;=&#x02009;36) and few patients (n&#x02009;=&#x02009;6) treated with azithromycin.</p><p id="Par15">To the contrary, another report on the use of a combination of hydroxicloroquine and azithromycin to treat COVID-19 patients showed no evidence of a strong of antiviral activity or clinical benefit from the use of the aforementioned drug association [<xref ref-type="bibr" rid="CR21">21</xref>].</p><p id="Par16">Very recently some australian researchers demonstrated that ivermectin, an Food and Drug Administration (FDA)&#x02014;approved anti-parasitic, have broad-spectrum anti-viral activity in vitro, with a single dose able to stop viral growth in 48&#x000a0;h [<xref ref-type="bibr" rid="CR22">22</xref>]. This effect can be explained by the inhibition of IMP&#x003b1;/&#x003b2;1 during infection impacting on cell division [<xref ref-type="bibr" rid="CR22">22</xref>].</p><p id="Par17">So far, researchers have proposed more than 30 drugs (remdesevir, favipiravir, darunavir/cobicistat, indinavir, saquinavir, carfilzomib, fosamprenavir, bortezomib, raltegravir, raltegravir, etc.&#x02026;) with possible activity against COVID-19 [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>].</p><p id="Par18">However, to date, the most promising antiviral drug able to fighting COVID-19 is the nucleotide prodrug remdesivir (GS-5734). This drug, recently involved in four phase III clinical trials in China and United States [<xref ref-type="bibr" rid="CR25">25</xref>], has a broad spectrum of antiviral activities against RNA viruses like filoviruses, paramyxoviruses, pneumoviruses, SARS and MERS coronavirus [<xref ref-type="bibr" rid="CR10">10</xref>].</p><p id="Par19">Based on pre-clinical studies in Ebola virus, remdesivir act as an inhibitor of RNA polymerase, thus determining a premature termination of viral RNA transcription [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR26">26</xref>].</p><p id="Par20">Animal experiments showed that remdesivir in combination with interferon can reduce the viral load in lung tissue of mice infected with MERS, consequently improving lung function and decreasing damage of the tissue [<xref ref-type="bibr" rid="CR13">13</xref>].</p><p id="Par21">Other studies suggests that a combination therapy of remdesivir with specific monoclonal antibodies could be the ideal therapeutic option for treat COVID-19 [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>].</p><p id="Par22">Tocilizumab, a drug approved by FDA for rheumatoid arthritis and cytokine release syndrome (CRS), seems to be helpful in patients infected with COVID-19. These patients can develop uncontrolled immune response leading to serious life-threatening damage to lung tissue. Tocilizumab is not active against the virus, however, inhibiting the interleukin-6 receptor it could decrease the&#x000a0;systemic inflammation (cytokine release storm) and consequently improve the prognosis [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>].</p><p id="Par23">Interesting suggestions for future treatments could be the development of type II transmembrane serine protease (TMPRSS2) inhibitors like camostat mesilate, approved in Japan for the treatment of pancreatic inflammation [<xref ref-type="bibr" rid="CR10">10</xref>]. This drug could act by blocking the entry of the virus inside lung cells and disabling the activation of the spike protein of SARS-CoV [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR31">31</xref>]. To be fully effective, it need to be used in combination with an Abelson (Abl) kinase inhibitors (i.e. the anticancer imatinib) which inhibits fusion of the virions at the endosomal membrane [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>].</p><p id="Par24">Finally, since the SARS-COV-2 uses angiotensin-converting enzyme 2 (ACE2) as the receptor binding domain for its spike protein, some authors hypothesize that angiotensin receptor 1 (AT1R) blockers such as losartan or telmisartan, could have some beneficial in patients infected by COVID-19 who experienced pneumonia [<xref ref-type="bibr" rid="CR33">33</xref>&#x02013;<xref ref-type="bibr" rid="CR35">35</xref>].</p><p id="Par25">To the present, there is only one retrospective study suggesting that COVID-19 patients with hypertension and already treated with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, showed better clinical outcome with respect to patients treated with other antihypertensive drugs [<xref ref-type="bibr" rid="CR36">36</xref>].</p><p id="Par26">Still, other authors suggest the opposite. The over-expression of cardiac ACE2 receptors in patients treated with these classes of drugs could expose them more to the virus [<xref ref-type="bibr" rid="CR37">37</xref>].</p><p id="Par27">As both these hypotheses are still unproven, this matter remains an interesting starting point for future studies.</p><p id="Par28">The challenge that awaits us tomorrow is to understand where we went wrong and if in these years we could have done more. When this pandemic finally will end, we will have to roll up our sleeves and work hard so that such events can no longer happen. If a new threat arises, now we must be prepared.</p><p id="Par29">Currently, none of the drugs on the market is really effective against COVID-19. The new antiviral drugs should ensure better pharmacokinetic properties, greater potency and/or a lower toxicity profile than currently available therapies. The combined use of multiple antiviral drugs is the right way&#x000a0;to go, so it is possible to increase antiviral activity, reduce the dosage of single drugs (and thus&#x000a0;toxicity), and prevent the development of resistance by providing a wider antiviral activity than single drug treatment&#x000a0;does. Identifying new molecular targets within the virus is also crucial [<xref ref-type="bibr" rid="CR37">37</xref>]. The new strategic therapies involve the use of drugs that modulate the host's immune response, drugs that stimulate the immune response, or virus-specific immunotherapies to boost the host's defenses.</p><p id="Par30">Prevention, control, active communication and investment in research are the only ways to overcome this and future challenges that humanity will face. When SARS, MERS or EBOLA spread, scientists started promising research, but when the epidemics finished, they didn't go on and look onward [<xref ref-type="bibr" rid="CR38">38</xref>]. From now on everything has to change. We must review the functioning and management of animal markets by increasing their safety, since these markets are the main places of origin of new zoonotic pathogens and therefore are high risk&#x000a0;areas for public health [<xref ref-type="bibr" rid="CR2">2</xref>]. We must then understand viruses, their origin and development better.</p><p id="Par31">Search for more effective and safer therapies is humanity's ultimate&#x000a0;challenge in the twenty-first century.</p><p id="Par32">Today we really had proof of this.</p></body><back><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes notes-type="funding-information"><title>Funding</title><p>None.</p></notes><notes notes-type="COI-statement"><title>Conflicts of interest</title><p>The authors declare that they have no relationships relevant to the contents of this paper to disclose.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other"><ext-link ext-link-type="uri" xlink:href="https://www.ecdc.europa.eu/en/geographical-distribution-2019-ncov-cases">https://www.ecdc.europa.eu/en/geographical-distribution-2019-ncov-cases</ext-link>. Accessed 17 Apr 2020.</mixed-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malta</surname><given-names>M</given-names></name><name><surname>Rimoin</surname><given-names>AW</given-names></name><name><surname>Strathdee</surname><given-names>SA</given-names></name></person-group><article-title>The coronavirus 2019-nCoV epidemic: Is hindsight 20/20?</article-title><source>EClinicalMedicine</source><year>2020</year><volume>20</volume><fpage>100289</fpage><pub-id pub-id-type="doi">10.1016/j.eclinm.2020.100289</pub-id><pub-id pub-id-type="pmid">32154505</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="other"><ext-link ext-link-type="uri" xlink:href="https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020">https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020</ext-link>. Accessed 13 Mar 2020.</mixed-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ji</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Zai</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>X</given-names></name></person-group><article-title>Cross-species transmission of the newly identified coronavirus 2019-nCoV</article-title><source>J Med Virol</source><year>2020</year><volume>92</volume><issue>4</issue><fpage>433</fpage><lpage>440</lpage><pub-id pub-id-type="doi">10.1002/jmv.25682</pub-id><pub-id pub-id-type="pmid">31967321</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Velavan</surname><given-names>TP</given-names></name><name><surname>Meyer</surname><given-names>CG</given-names></name></person-group><article-title>The COVID-19 epidemic</article-title><source>Trop Med Int Health</source><year>2020</year><volume>25</volume><issue>3</issue><fpage>278</fpage><lpage>280</lpage><pub-id pub-id-type="doi">10.1111/tmi.13383</pub-id><pub-id pub-id-type="pmid">32052514</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>P</given-names></name><name><surname>Lu</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>C</given-names></name><name><surname>Sun</surname><given-names>W</given-names></name><name><surname>Pan</surname><given-names>B</given-names></name></person-group><article-title>Understanding of COVID-19 based on current evidence</article-title><source>J Med Virol.</source><year>2020</year><volume>92</volume><fpage>548</fpage><lpage>551</lpage><pub-id pub-id-type="doi">10.1002/jmv.25722</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fehr</surname><given-names>AR</given-names></name><name><surname>Perlman</surname><given-names>S</given-names></name></person-group><article-title>Coronaviruses: an overview of their replication and pathogenesis</article-title><source>Methods Mol Biol</source><year>2015</year><volume>1282</volume><fpage>1</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1007/978-1-4939-2438-7_1</pub-id><pub-id pub-id-type="pmid">25720466</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Guo</surname><given-names>D</given-names></name></person-group><article-title>Emerging coronaviruses: genome structure, replication, and pathogenesis</article-title><source>J Med Virol</source><year>2020</year><volume>92</volume><issue>4</issue><fpage>418</fpage><lpage>423</lpage><pub-id pub-id-type="doi">10.1002/jmv.25681</pub-id><pub-id pub-id-type="pmid">31967327</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>N</given-names></name><name><surname>Zhang</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><etal/></person-group><article-title>A novel coronavirus from patients with pneumonia in China, 2019</article-title><source>N Engl J Med</source><year>2020</year><volume>382</volume><issue>8</issue><fpage>727</fpage><lpage>733</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2001017</pub-id><pub-id pub-id-type="pmid">31978945</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez</surname><given-names>MA</given-names></name></person-group><article-title>Compounds with therapeutic potential against novel respiratory 2019 coronavirus</article-title><source>Antimicrob Agents Chemother</source><year>2020</year><volume>64</volume><fpage>e00399</fpage><pub-id pub-id-type="doi">10.1128/AAC.00399-20</pub-id><pub-id pub-id-type="pmid">32152082</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chu</surname><given-names>CM</given-names></name><name><surname>Cheng</surname><given-names>VC</given-names></name><name><surname>Hung</surname><given-names>IF</given-names></name><etal/></person-group><article-title>Role of LOPINAVIR/ritonavir in the treatment of SARS: initial virological and clinical findings</article-title><source>Thorax</source><year>2004</year><volume>59</volume><issue>3</issue><fpage>252</fpage><lpage>256</lpage><pub-id pub-id-type="doi">10.1136/thorax.2003.012658</pub-id><pub-id pub-id-type="pmid">14985565</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Wen</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><etal/></person-group><article-title>Trial of lopinavir&#x02013;ritonavir in adults hospitalized with severe Covid-19</article-title><source>N Engl J Med</source><year>2020</year><pub-id pub-id-type="doi">10.1056/NEJMoa2001282</pub-id><?supplied-pmid 32369286?><pub-id pub-id-type="pmid">32369286</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>L</given-names></name><name><surname>Hu</surname><given-names>S</given-names></name><name><surname>Gao</surname><given-names>J</given-names></name></person-group><article-title>Discovering drugs to treat coronavirus disease 2019 (COVID-19)</article-title><source>Drug Discov Ther</source><year>2020</year><volume>14</volume><issue>1</issue><fpage>58</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.5582/ddt.2020.01012</pub-id><pub-id pub-id-type="pmid">32147628</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="other"><ext-link ext-link-type="uri" xlink:href="https://www.chinalawtranslate.com/coronavirus-treatment-plan-7/?lang=en">https://www.chinalawtranslate.com/coronavirus-treatment-plan-7/?lang=en</ext-link>. Accessed 17 Apr 2020.</mixed-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Qi</surname><given-names>C</given-names></name><name><surname>Shen</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>J</given-names></name></person-group><article-title>Clinical trial analysis of 2019-nCoV therapy registered in China</article-title><source>J Med Virol</source><year>2020</year><volume>92</volume><fpage>540</fpage><lpage>545</lpage><pub-id pub-id-type="doi">10.1002/jmv.25733</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gautret</surname><given-names>P</given-names></name><name><surname>Lagier</surname><given-names>JC</given-names></name><name><surname>Parola</surname><given-names>P</given-names></name><etal/></person-group><article-title>Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial</article-title><source>Int J Antimicrob Agents</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2020.105949</pub-id><?supplied-pmid 32205204?><pub-id pub-id-type="pmid">32205204</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Savarino</surname><given-names>A</given-names></name><name><surname>Di Trani</surname><given-names>L</given-names></name><name><surname>Donatelli</surname><given-names>I</given-names></name><name><surname>Cauda</surname><given-names>R</given-names></name><name><surname>Cassone</surname><given-names>A</given-names></name></person-group><article-title>New insights into the antiviral effects of chloroquine</article-title><source>Lancet Infect Dis</source><year>2006</year><volume>6</volume><issue>2</issue><fpage>67</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(06)70361-9</pub-id><pub-id pub-id-type="pmid">16439323</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Devaux</surname><given-names>CA</given-names></name><name><surname>Rolain</surname><given-names>JM</given-names></name><name><surname>Colson</surname><given-names>P</given-names></name><name><surname>Raoult</surname><given-names>D</given-names></name></person-group><article-title>New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?</article-title><source>Int J Antimicrob Agents</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2020.105938</pub-id><?supplied-pmid 32179150?><pub-id pub-id-type="pmid">32179150</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amsden</surname><given-names>GW</given-names></name></person-group><article-title>Anti-inflammatory effects of macrolides&#x02014;an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions?</article-title><source>J Antimicrob Chemother</source><year>2005</year><volume>55</volume><issue>1</issue><fpage>10</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1093/jac/dkh519</pub-id><pub-id pub-id-type="pmid">15590715</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwiatkowska</surname><given-names>B</given-names></name><name><surname>Ma&#x0015b;li&#x00144;ska</surname><given-names>M</given-names></name></person-group><article-title>Macrolide therapy in chronic inflammatory diseases</article-title><source>Mediat Inflamm</source><year>2012</year><volume>2012</volume><fpage>636157</fpage><pub-id pub-id-type="doi">10.1155/2012/636157</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Molina</surname><given-names>JM</given-names></name><name><surname>Delaugerre</surname><given-names>C</given-names></name><name><surname>Goff</surname><given-names>JL</given-names></name><etal/></person-group><article-title>No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection</article-title><source>Med Mal Infect</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.medmal.2020.03.006</pub-id><?supplied-pmid 32240719?><pub-id pub-id-type="pmid">32240719</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caly</surname><given-names>L</given-names></name><name><surname>Druce</surname><given-names>JD</given-names></name><name><surname>Catton</surname><given-names>MG</given-names></name><name><surname>Jans</surname><given-names>DA</given-names></name><name><surname>Wagstaff</surname><given-names>KM</given-names></name></person-group><article-title>The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro</article-title><source>Antivir Res</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.antiviral.2020.104787</pub-id><?supplied-pmid 32251768?><pub-id pub-id-type="pmid">32251768</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><mixed-citation publication-type="other"><ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04304053?term=cobicistat&#x00026;cond=covid-19&#x00026;phase=2&#x00026;draw=2&#x00026;rank=1">https://clinicaltrials.gov/ct2/show/NCT04304053?term=cobicistat&#x00026;cond=covid-19&#x00026;phase=2&#x00026;draw=2&#x00026;rank=1</ext-link>. Accessed 17 Apr 2020.</mixed-citation></ref><ref id="CR24"><label>24.</label><mixed-citation publication-type="other"><ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04252274?term=cobicistat&#x00026;cond=covid-19&#x00026;phase=2&#x00026;draw=2&#x00026;rank=2">https://clinicaltrials.gov/ct2/show/NCT04252274?term=cobicistat&#x00026;cond=covid-19&#x00026;phase=2&#x00026;draw=2&#x00026;rank=2</ext-link>. Accessed 17 Apr 2020.</mixed-citation></ref><ref id="CR25"><label>25.</label><mixed-citation publication-type="other"><ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/results?term=remdesivir&#x00026;cond=COVID-19&#x00026;phase=2">https://clinicaltrials.gov/ct2/results?term=remdesivir&#x00026;cond=COVID-19&#x00026;phase=2</ext-link>. Accessed 17 Apr 2020.</mixed-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mulangu</surname><given-names>S</given-names></name><name><surname>Dodd</surname><given-names>LE</given-names></name><name><surname>Davey</surname><given-names>RT</given-names><suffix>Jr</suffix></name><etal/></person-group><article-title>A randomized, controlled trial of Ebola virus disease therapeutics</article-title><source>N Engl J Med</source><year>2019</year><volume>381</volume><issue>24</issue><fpage>2293</fpage><lpage>2303</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1910993</pub-id><pub-id pub-id-type="pmid">31774950</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malik</surname><given-names>YS</given-names></name><name><surname>Sircar</surname><given-names>S</given-names></name><name><surname>Bhat</surname><given-names>S</given-names></name><etal/></person-group><article-title>Emerging novel coronavirus (2019-nCoV)&#x02014;current scenario, evolutionary perspective based on genome analysis and recent developments</article-title><source>Vet Q</source><year>2020</year><volume>40</volume><issue>1</issue><fpage>68</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1080/01652176.2020.1727993</pub-id><pub-id pub-id-type="pmid">32036774</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>J</given-names></name></person-group><article-title>New coronavirus threat galvanizes scientists</article-title><source>Science</source><year>2020</year><volume>367</volume><issue>6477</issue><fpage>492</fpage><lpage>493</lpage><pub-id pub-id-type="doi">10.1126/science.367.6477.492</pub-id><?supplied-pmid 32001631?><pub-id pub-id-type="pmid">32001631</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scott</surname><given-names>LJ</given-names></name></person-group><article-title>Tocilizumab: a review in rheumatoid arthritis</article-title><source>Drugs</source><year>2017</year><volume>77</volume><issue>17</issue><fpage>1865</fpage><lpage>1879</lpage><pub-id pub-id-type="doi">10.1007/s40265-017-0829-7</pub-id><pub-id pub-id-type="pmid">29094311</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>JW</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>GQ</given-names></name></person-group><article-title>The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality</article-title><source>Int J Antimicrob Agents</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2020.105954</pub-id><?supplied-pmid 32335274?><pub-id pub-id-type="pmid">32335274</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glowacka</surname><given-names>I</given-names></name><name><surname>Bertram</surname><given-names>S</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response</article-title><source>J Virol</source><year>2011</year><volume>85</volume><issue>9</issue><fpage>4122</fpage><lpage>4134</lpage><pub-id pub-id-type="doi">10.1128/JVI.02232-10</pub-id><pub-id pub-id-type="pmid">21325420</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coleman</surname><given-names>CM</given-names></name><name><surname>Sisk</surname><given-names>JM</given-names></name><name><surname>Mingo</surname><given-names>RM</given-names></name><name><surname>Nelson</surname><given-names>EA</given-names></name><name><surname>White</surname><given-names>JM</given-names></name><name><surname>Frieman</surname><given-names>MB</given-names></name></person-group><article-title>Abelson kinase inhibitors are potent inhibitors of severe acute respiratory syndrome coronavirus and middle east respiratory syndrome coronavirus fusion</article-title><source>J Virol</source><year>2016</year><volume>90</volume><issue>19</issue><fpage>8924</fpage><lpage>8933</lpage><pub-id pub-id-type="doi">10.1128/JVI.01429-16</pub-id><pub-id pub-id-type="pmid">27466418</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>ML</given-names></name><name><surname>Yang</surname><given-names>JM</given-names></name><name><surname>Sun</surname><given-names>YP</given-names></name><name><surname>Su</surname><given-names>GH</given-names></name></person-group><article-title>Inhibitors of RAS might be a good choice for the therapy of COVID-19 pneumonia</article-title><source>Zhonghua Jie He He Hu Xi Za Zhi</source><year>2020</year><volume>43</volume><issue>3</issue><fpage>219</fpage><lpage>222</lpage><?supplied-pmid 32164092?><pub-id pub-id-type="pmid">32164092</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>R</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><etal/></person-group><article-title>Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding</article-title><source>Lancet</source><year>2020</year><volume>395</volume><issue>10224</issue><fpage>565</fpage><lpage>574</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30251-8</pub-id><pub-id pub-id-type="pmid">32007145</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gurwitz</surname><given-names>D</given-names></name><etal/></person-group><article-title>Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics</article-title><source>Drug Dev Res</source><year>2020</year><pub-id pub-id-type="doi">10.1002/ddr.21656</pub-id><?supplied-pmid 32129518?><pub-id pub-id-type="pmid">32129518</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meng</surname><given-names>J</given-names></name><name><surname>Xiao</surname><given-names>G</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><etal/></person-group><article-title>Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension</article-title><source>Emerg Microbes Infect</source><year>2020</year><volume>9</volume><issue>1</issue><fpage>757</fpage><lpage>760</lpage><pub-id pub-id-type="doi">10.1080/22221751.2020.1746200</pub-id><pub-id pub-id-type="pmid">32228222</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><mixed-citation publication-type="other">Goodman &#x00026; Gilman. Le basi farmacologiche della terapia. X Edizione. 2003. Cap.50, pag. 1275.</mixed-citation></ref><ref id="CR38"><label>38.</label><mixed-citation publication-type="other"><ext-link ext-link-type="uri" xlink:href="https://time.com/5819965/coronavirus-treatments-research/">https://time.com/5819965/coronavirus-treatments-research/</ext-link>. Accessed 17 Apr 2020.</mixed-citation></ref></ref-list></back></article>